2026 Global Sales TOP15 Forecast List Released! Roche, Pfizer and Johnson and Johnson are firmly in the top three, with the drug companies set to top $50 billion.

News Of the global sales top15 forecast list released by 2026! Roche, Pfizer (PFEUS), Johnson and Johnson (JNJUS) Firmly In the top three July 14, 2020 20:54:51 E Pharmaceutical Manager Recently, EvaluatePharma released the 2026 sales top15 pharmaceutical company forecast, despite the threat of generic drugs, Roche is still favored in the first place, Pfizer, Johnson and Johnson also ranked in the top three, AZ, BMS, Lilly or into 2026 the fastest growing enterprises, innovative pharmaceutical research and development enterprises are the largest competitivenessThe 21st century has entered its third decade, and new drugs have become a well-deserved theme of the last decade, and in terms of recent mergers and acquisitions, spin-offs and other pharmaceutical companies, they will focus more on new products and technologies in the third decadeAlthough the world is facing unprecedented "big plague" health events since the start of 2020, analysts say growth in pharmaceutical companies is continuingOn July 13th EvaluatePharma released a forecast for pharmaceutical companies with top15 sales by 2026In this forecast, EvaluatePharma evaluates pharmaceutical companies' product sales, research and development pipelines, transactions, and restructuring, and evaluates the pharmaceutical company's sales growthNowhere is it more notable than Roche at the top of the TOP15 listIn the past five years, Roche's three masters - Zirabev, the product name: Anvitin, Rituscione, commodity name: Merova) and Quzimera (trazimera, commodity name: Herceptin) have faced patent expiration challenges, and Roche is surprisingly ranked first in the Evaluate Pharma listEvaluate Pharma also predicts that generics of its three products are expected to break the $10 billion profit gapHowever, analysts also believe that Roche's innovative drugs in the fields of oncology, haemophilia and multiple sclerosis, such as tas, hemophilia and multiple sclerosis, will drive Roche's future sales growth, while analysts are bullish on Roche's efforts to maintain patents on the three home-grown productsMergers and break-ups by pharmaceutical companies could also affect EvaluatePharma's predictions for a company, such as AbbVie's massive merger with Ayr in May, which is facing a multibillion-dollar market loss as the patent expires and generics go on the market, but through a deal with Al-Ayr, EvaluatePharma believes AbbVie can make the list of pharmaceutical companies with top5 sales by 2026In terms of specific amounts, EvaluatePharma believes that the top six companies - Roche, Pfizer, Johnson and Johnson, Novartis, Abbvie and Mersadon - will all have sales of more than $50 billion by 2026, a forecast that, in addition to the six companies' existing research and development pipelines and layouts, has joined the research and development queueforing drugs and vaccines for health events, which is undoubtedly a huge market in terms of the current global health eventsWhile the six companies are projected to generate huge amounts of sales on specific sales, that doesn't mean they are growing fastestIn terms of growth, EvaluatePharma also forecasts that AZ and BMS will be the two fastest-growing companies in the world by 2026, with EvaluatePharma arguing that AZ and BMS sales will grow at 8.47 per cent and 8.23 per cent a year respectively by 2026, in addition to more than 5 per cent growth in Lilly, Novo and NordiskIn addition, compared with the previous list of pharmaceutical companies with global revenue TOP20 released by FiercePharma in 2019, the forecast seditum for pharmaceutical companies with TOP15 sales by 2026 appears to be very similar, with Johnson and Johnson, Roche and Pfizer still firmly in the top three, but it is worth noting that Takeda, the Asian company that made the top 10 for the first time in 2019, also ranked 11th in the forecast listPointing the way - 2019 global TOP 20 pharmaceutical companies shuffle, The first time Asian pharmaceutical companies among the top 10, biological similar drugs threat attack! Mapping: E Drug Manager 1 Roche's 2026 sales: $61.9 billion 2019 sales: $48.2 billion 2019-26 compound annual growth: 3.62% Over the years, Roche's super-heavyweight cancer drug "Three Swordsmen": Herceptin, Avastin and Ritanux have dominated the world's top three cancer-fighting drugs But two biosimilars of Amgen and Herceptin, created by Amgen and Al-Jian, have entered the market, and perhaps Roche's status as an anti-tumor drug "carrying son" is coming to an end In addition, the FDA quickly approved Enhertu of AstraZeneca and Sansukpharmaceuticals, a major threat to Roche's heavy-bomb anti-breast cancer drugs Roche expects biosimilars to cost $10 billion to the three major cancer drugs by 2023 Sales of these three drugs have fallen from 20.6 billion Swiss francs ($21.8 billion) the year before to 19.6 billion Swiss francs last year, when generics began entering the U.S market in mid-2019 Roche is beginning to feel the power of biosimilar attacks, and even its growth-driven new drugs could be threatened by competitors Despite this, Roche's pharmaceutical division generated $63.54 billion in sales in 2019, while Roche's three major cancer drugs generated $19.86 billion in sales in 2019 The company has also been trying to mitigate the impact of genericdrugs by introducing new drugs, which so far have worked 2 Pfizer (PFE US) Projected 2026 Sales: $56.1 Billion 2019 Sales: $46.1 billion 2019-26 COMPOUND annual growth rate: 2.83% Pfizer's merger of Mylan and Pfizer's patent-expired brand and generics business, Pugen, to create a new global pharmaceutical company was announced as a result of THE announcement of COVID-19 However, there were no additional changes to the previously announced terms of the deal and the merger plan, and the two companies remain confident that the upcoming deal will benefit their shareholders and other stakeholders The assessment predicts that Pfizer's current revenue will grow 2.83 percent to $56.1 billion by 2026, more than $5 billion more than total revenue in 2019 To do so, Pfizer needs to rely on its lucrative biopharmaceutical brand, which posted a staggering 12 per cent growth in the first quarter with revenues of just over $10bn At the same time, Pfizer is once again in trouble, with sales plummeting 37 per cent in the quarter to just over $2bn, and it's no wonder Pfizer is slimming down 3 Johnson and Johnson (JNJ US) Projected 2026 Sales: $54.6 Billion 2019 Sales: $42.4 billion 2019-26 CAGR: 3.75% of Johnson and Johnson's business covers pharmaceuticals, healthcare and medical devices But over the years, its pharmaceutical group has outperformed other sectors, driven by growth in sales of anti-tumor and immuno-drugs Johnson and Johnson has put a heavy bets on the pharmaceutical business, with new product launches and brand expansion predicting that sales growth will put the company's sales at more than $54 billion by 2026, enough to make it into the world's top three There are also the best and the laggards in Johnson and Johnson's pharmaceutical group Utek sing-it-up, now the highest-selling drug for Johnson and Johnson, is a 25 percent increase of $6.3 billion in 2019, a huge breakthrough anyway The immunology drug Tremfya, the blood cancer treatment drug Darzalex, and the diabetes drug Imbruvica all posted strong growth In 2019, Johnson and Johnson's pharmaceutical sales were $42.2 billion, up 5.8 percent year-on-year, outpacing the 3 percent growth in consumer healthcare Sales of medical equipment were $29.63 billion, down 1.7 percent from a year earlier 4.Novartis (NVS US) Projected 2026 Sales: $54.25 Billion 2019 Sales: $46.08 billion 2019-26 CAGr: 2.36% Novartis has a broad portfolio of star drugs in immunology, cardiology, neuroscience, oncology, and more At the same time, the company is actively expanding its market, both providing new indications for existing drugs and introducing new treatments The company is pushing five new drugs with great potential: sickle cell therapy Adakveo, eye injection Beovu, multiple sclerosis therapy Mayzent, breast cancer drug Piqray and gene therapy Zolgensma Meanwhile, Novartis' Entresto sales rose 71 percent to $1.73 billion in heart medicine Novartis continues to strive to become a top pharmaceutical company The company sold its over-the-counter drug business to its joint venture partner, GlaxoSmithKline, divested Alcon, an eye care technology company, but also acquired Shire's Xiidra to bolster its eye drug franchise and buy med inclisiran, a company that makes cholesterol-lowering drugs 5 ABBV US) Projected 2026 Sales: $53.56 billion (including Alkken) 2019 sales: $32.35 billion 2019-26 COMPOUND annual growth: 1.84% 2019, AbbVie's net revenue reached $33.27 billion, mainly due to basically stable sales of Humira, as well as blood cancer drugs, AndVenc Of all the companies on the list, AbbVie changed the most last year when it acquired Allergan in 2019 Experts predict that the company's revenues will face significant challenges in the years to 2026 For the first time in years, The Eberve's bomb-heavy immuno-drug Humira is in trouble as biosimilars hit the European market But for AbbVie, the future looks bright, even as its sales force loses momentum 6 Mercaydon (MRK US) Projected 2026 Sales: $51.96 Billion 2019 Sales: $40.9 billion 2019-26 CAGR: 3.48% Driven by "superstar" Paboli Zuma in immuno-oncology, Mercado achieved strong growth in 2019, with global sales of $46.84 billion The company's best-selling product to date is expected to reach $14.4 billion this year and $24.3 billion in 2026 Mercado is also a leader in the vaccine market Its HPV vaccine, Jadasio, continued to climb last year, with revenues of $3.7 billion in 2019, up 19 percent As global health events continue to spread, Mercado also announced three major plans to combat health events, including the acquisition of Themis Bioscience, which focuses on vaccines and immunomodulation therapies for infectious diseases; The move follows the announcement of fourth-quarter 2019 results, which it announced would spin off its Women's Health, Traditional Brands and Biosimilars, and create a new company that is expected to generate about $6.5 billion in revenue by 2020 The company expects the deal to close in the first half of 2021 7.Sanofi (SNY US) Projected 2026 Sales: $49.5 Billion 2019 Sales: $40.17 billion 2019-26 CAGR: 3.03% Sanofi is turning to the therapeutic areas it believes can lead, rather than cardiovascular and diabetes At a strategy launch in December 2019, Sanofi said it would pull out of research and development in those areas and invest more in other areas Another important part of Sanofi's future is Dupixent We are committed to converting the drug into a product of 10 billion euros a year Sanofi is launching this indication globally and adding new approvals to key markets following the initial approval of tertomatitis At the same time, Sanofi is expanding its oncology field and this year received approval for sarclisa, a multiple myeloma The drug is Sanofi's first FDA-approved wholly-owned oncology drug in a decade, and an executive at the company said it represented the drug maker's "return to cancer." 8.GSK (GSK US) Projected 2026 Sales: $47.5 Billion 2019 Sales: $37.07 billion 2019-26 CAGR: 3.6% With shingles vaccine Shingrix approved, GSK's share price soared in 2019 In addition, respiratory sales increased by 38% in the first quarter of 2020, driven by GSK's new chronic obstructive pulmonary disease drug Trelegy and the severe asthma drug Mepolision In addition, in August 2019, GSK announced that it had completed a deal with Pfizer to consolidate its consumer health products business and form a world-leading joint venture Based on scientific innovation, the joint venture is a global leader in OTC products and ranks first or second in market share in all key regions, including the United States and China 9.BMS Projected 2026 Sales: $43.8 Billion 2019 Sales: $25.17 billion 2019-26 compound annual growth: 8.23% Attribut the company's rise thanks to the cancer drug Opdivo and blood thinner Eliquis, as well as the acquisition of gene at the end of last year As early as last November, BMS completed a massive acquisition of Celgene Earlier this year, the drugmaker announced its transformation into one of the largest biopharmaceutical companies in 2020 Celgene, an anticancer company, is expected to generate $11.75 billion in revenue for BMS in 2026, up nearly 46 percent from its 2019 sales of $8.06 billion Evaluate Pharma ranks The PD-1 inhibitor Opdivo as the third-higher-selling drug in 2026 However, BMS's Opdivo will face stiff competition from Merck's Keytruda BMS hopes for the nearest.